Bank Of New York Mellon Corp Salarius Pharmaceuticals, Inc. Transaction History

Bank Of New York Mellon Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.16 - $0.42 $38 - $101	-241 Reduced 0.68%	35,265 $7,000
Q2 2021 Aug 11, 2021	SELL	$1.02 - $1.52 $6,602 - $9,838	-6,473 Reduced 15.42%	35,506 $37,000
Q1 2021 May 13, 2021	SELL	$1.0 - $3.0 $3,028 - $9,084	-3,028 Reduced 6.73%	41,979 $62,000
Q3 2020 Nov 12, 2020	SELL	$0.77 - $1.52 $138 - $273	-180 Reduced 0.4%	45,007 $37,000
Q1 2020 May 06, 2020	BUY	$0.56 - $3.82 $25,304 - $172,614	45,187 New	45,187 $30,000

Ticker SLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,244,650
Market Cap $3.37M
Description
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a ...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.